Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance

Cytokinetics IncTrade
Consumer Discretionary Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. Which is the better fit depends on your goals.

CYTKXLY
Market Cap
$10.63B
Sector
Technology
52-Week High
$87.26$124.52
52-Week Low
$34.31$105.64
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.

The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.

Consumer Discretionary Select Sector SPDR Fund

XLY trades at $117.89, down 1.49% today, but maintains a bullish technical outlook with strong moving average support. The ETF benefits from positive analyst sentiment with a 100% buy rating and recent coverage highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions with RSI readings above 70, but the overall trend remains positive with key support at $118.

The consumer discretionary sector faces headwinds from inflation pressures, but XLY's diversified exposure positions it for recovery. Near-term risks include consumer spending sensitivity to economic conditions, while the bullish analyst consensus and technical momentum suggest potential upside if market conditions stabilize.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Consumer Discretionary Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.

Read more on XLY